A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
Purpose
The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in combination with standard of care (SOC) in adult patients with mild COVID-19 (coronavirus disease 2019). The trial will also define the recommended phase 2 dose (RP2D) of bempegaldesleukin in patients with mild COVID-19.
Conditions
- Covid-19
- Coronavirus Disease 2019
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male or female patients, age 18 years or older on the day of signing the informed consent form. - Agrees to admission to an in-patient facility for monitoring from Days 1 to 8, inclusive. - Symptoms of mild illness with COVID-19 without shortness of breath, dyspnea, or clinical signs indicative of more serious COVID-19. - Laboratory confirmed SARS-CoV-2 infection within 4 days prior to the screening visit or during the 7-day screening period. - Respiratory rate < 20 breaths per minute, heart rate < 90 beats per minute (bpm). - Oxygen saturation by pulse oximetry > 93% on room air. - Body mass index < 35 kg/m2. - Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min. - Alanine transaminase (ALT) or aspartate transaminase (AST) < 2 x upper limit of normal (ULN) and total bilirubin < 1.5 x ULN. - Agrees to not participate in another clinical trial for the treatment of COVID-19 while on study unless the patient's condition has worsened and is considered to be moderate, severe, or critical by the Investigator.
Exclusion Criteria
- Shortness of breath, hypoxia, or signs of serious lower airway disease. - C-reactive protein, lactate dehydrogenase (LDH), or interleukin-6 (IL-6) > 1.5 x ULN. - D-dimer or ferritin > 1.5 x ULN. - Imminently requiring, or currently on, mechanical ventilation or extracorporeal membrane oxygenation (ECMO). - Systolic blood pressure < 90 mm Hg or diastolic blood pressure < 60 mm Hg. - Evidence of acute respiratory distress syndrome (ARDS) or systemic inflammatory response syndrome (SIRS)/shock. - Known cardiovascular history, including unstable or deteriorating cardiac disease. - Autoimmune disease. - History of pulmonary embolism (PE), deep vein thrombosis (DVT), or prior clinically significant venous or non-cerebrovascular accident/transient ischemic attack arterial thromboembolic event. - Central nervous system disease or dysfunction. - Requirement for > 2 anti-hypertensive medications. - Unwilling to refrain from alcohol consumption from Day 1 of admission to the in-patient facility until discharge from the facility. - Adrenal insufficiency. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Bempegaldesleukin IV + Standard of Care |
|
|
Placebo Comparator Placebo + Standard of Care |
|
Recruiting Locations
More Details
- NCT ID
- NCT04646044
- Status
- Completed
- Sponsor
- Nektar Therapeutics